Abstract
The DOLULAM study assessed the efficacy of dolutegravir + lamivudine dual therapy to maintain virological suppression in heavily treatment-experienced HIV-1-infected adults. No virological failure occurred during the first year of the dual therapy. A virological substudy was conducted to assess the prevalence of M184I/V mutations at dual therapy initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS). HIV-1 RT sequences were obtained from DNA and/or historical RNA using Sanger technology. HIV-1 DNA RT and integrase NGS was performed using Illumina® technology. Among the 27 patients enrolled in the DOLULAM study, historical HIV DNA and RNA Sanger sequences were available in 14 and 18 patients, respectively. At the initiation of DOLULAM, DNA NGS genotypes showed that 45% and 21% of the patients harboured minority resistant variants (MRV) in RT and integrase, respectively. Combining all available genotype data, an M184I/V was observed in 17 of 27 (63%) of the patients. Most M184V were detected in historical RNA genotypes (n = 8 of 11), whereas M184I were exclusively detected in DNA genotypes (n = 10, including 7 as MRV). Ten patients displayed defective viral genomes in ...Continue Reading
References
Oct 1, 1993·Antimicrobial Agents and Chemotherapy·C A BoucherJ M Cameron
Aug 1, 2008·PLoS Medicine·Jeffrey A JohnsonWalid Heneine
Nov 9, 2010·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Karin J MetznerHauke Walter
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Marc WirdenVincent Calvez
Jun 13, 2012·The Journal of Antimicrobial Chemotherapy·Slim FouratiAnne Geneviève Marcelin
Jun 15, 2012·AIDS·Slim FouratiAnne-Geneviève Marcelin
Dec 18, 2015·The Journal of Antimicrobial Chemotherapy·Pierre GantnerJade Ghosn
Jan 29, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Eve TodescoLaurence Morand-Joubert
Jun 12, 2016·The Journal of Antimicrobial Chemotherapy·C KatlamaA-G Marcelin
Jul 2, 2016·AIDS·Maureen OliveiraMark A Wainberg
Feb 6, 2017·The Lancet. HIV· The Lancet Hiv
Mar 24, 2017·The Journal of Antimicrobial Chemotherapy·L AssoumouUNKNOWN ANRS AC-11 Resistance Study Group
Citations
Feb 10, 2018·AIDS·Diego Ripamonti, Maurizio Zazzi
Mar 13, 2018·The Journal of Antimicrobial Chemotherapy·Charlotte CharpentierRoland Landman
Sep 9, 2019·Current Infectious Disease Reports·Neha Sheth PanditSarah M Michienzi
Jan 3, 2020·AIDS·Mounerou SalouMartine Peeters
Feb 20, 2020·The Journal of Antimicrobial Chemotherapy·Josephine BriceSidonie Lambert-Niclot
Feb 24, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Romina QuerciaDaniel Kuritzkes
Mar 15, 2019·AIDS·Antonella CastagnaUNKNOWN DAU Study Group
Jul 7, 2018·Open Forum Infectious Diseases·Roberta GagliardiniUNKNOWN ARCA Study Group
Jul 18, 2020·Viruses·Keylie M GibsonKeith A Crandall
Aug 24, 2018·The Journal of Antimicrobial Chemotherapy·Narjis BoukliLaurence Morand-Joubert
Jun 7, 2018·The Journal of Antimicrobial Chemotherapy·T NguyenA G Marcelin
Nov 18, 2020·The Journal of Antimicrobial Chemotherapy·David Rial-CresteloUNKNOWN PI16/00837-PI16/00678 study group
Feb 25, 2021·The Journal of Antimicrobial Chemotherapy·Constance DelaugerreUNKNOWN ANRS 12286/MOBIDIP study group
Mar 19, 2021·The Journal of Antimicrobial Chemotherapy·Santiago Jiménez de OryUNKNOWN Paediatric Cohort of the Spanish National AIDS Network (CoRISpe and CoRISpe-FARO)
May 6, 2021·Diagnostics·Valeria Cento, Carlo Federico Perno
Aug 25, 2021·Infectious Diseases and Therapy·Rickesh PatelJustin Koteff
Aug 31, 2021·The Journal of Antimicrobial Chemotherapy·Rocio MontejanoJosé Ramón Arribas
Oct 16, 2021·The Journal of Antimicrobial Chemotherapy·Colin DeschanvresUNKNOWN Dat’AIDS Study Group
Dec 7, 2021·International Journal of Antimicrobial Agents·Daniele ArmeniaUNKNOWN PRESTIGIO Registry Study Group